A Somerset family has taken their fight for NHS-funded medical cannabis to the heart of government, meeting with Parliamentary Under-Secretary of State for Health Innovation and Safety, Zubir Ahmed.

Six-year-old Clover, who suffers from Aicardi Syndrome, relies on cannabis oil to manage dozens of daily seizures. Her parents, Emily and Spencer, report that the treatment has been transformative, reducing her seizures to just a few mild episodes per day. However, the family is currently forced to fund the medication privately at a cost of £750 per month—a total expenditure of £60,000 to date.

The Barrier to NHS Access

While medical cannabis was legalised in the UK in 2018, access remains severely restricted. The NHS currently only funds specific cannabis-based medicines that have undergone rigorous trials and received approval from the National Institute for Health and Care Excellence (NICE). Because the specific oil used by Clover has not yet cleared these bureaucratic hurdles, families are often left to navigate the expensive private market.

Following a meeting facilitated by their MP, Anna Sabine, the family expressed optimism about a "clear course of action" discussed with the minister. The Department of Health maintains that it funds licensed medicines where there is "clear evidence of their quality, safety, and effectiveness," placing the onus on manufacturers to seek formal approval.

For patients and advocates, this case highlights the ongoing gap between the legal status of medical cannabis and the reality of patient access. Reformers continue to argue that the current system places an undue financial burden on families and fails to recognise the clinical benefits reported by patients like Clover.

Source: BBC News